AstraZeneca Plc (AZN)

40.12
0.61 1.50
NYSE : Health Technology
Prev Close 40.73
Open 40.52
Day Low/High 40.06 / 40.59
52 Wk Low/High 35.30 / 43.30
Volume 3.71M
Avg Volume 3.31M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 104.84B
EPS 0.80
P/E Ratio 18.26
Div & Yield 1.37 (3.40%)

Latest News

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE ® (acalabrutinib) significantly prolonged the time patients...

LOKELMA™ Demonstrated Efficacy In Treating Hyperkalemia In Patients With End-Stage Renal Disease On Hemodialysis

LOKELMA™ Demonstrated Efficacy In Treating Hyperkalemia In Patients With End-Stage Renal Disease On Hemodialysis

AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium cyclosilicate) for the treatment of hyperkalemia in patients with end-stage renal disease (ESRD) on...

FARXIGA Study Showed Reduced Progression Of Kidney Disease Or Renal Death In Patients With Type 2 Diabetes

FARXIGA Study Showed Reduced Progression Of Kidney Disease Or Renal Death In Patients With Type 2 Diabetes

A pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showed that FARXIGA (dapagliflozin) reduced the progression of...

IMFINZI® (Durvalumab) Is The Only Immunotherapy To Demonstrate Overall Survival At Three Years In Unresectable, Stage III Non-Small Cell Lung Cancer

IMFINZI® (Durvalumab) Is The Only Immunotherapy To Demonstrate Overall Survival At Three Years In Unresectable, Stage III Non-Small Cell Lung Cancer

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of IMFINZI ® (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual...

Bob Harper And AstraZeneca Expand Survivors Have Heart Initiative To Empower And Unite Heart Attack Survivors Nationwide

Bob Harper And AstraZeneca Expand Survivors Have Heart Initiative To Empower And Unite Heart Attack Survivors Nationwide

AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite...

FASENRA® (benralizumab) Reduces Oral Corticosteroid Use And Maintains Long-term Efficacy And Safety Profile In Severe Eosinophilic Asthma

FASENRA® (benralizumab) Reduces Oral Corticosteroid Use And Maintains Long-term Efficacy And Safety Profile In Severe Eosinophilic Asthma

A new integrated analysis of Phase III data for FASENRA ® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and...

AstraZeneca Continues To Redefine Cancer Treatment At The 2019 ASCO Annual Meeting

AstraZeneca Continues To Redefine Cancer Treatment At The 2019 ASCO Annual Meeting

AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA ® (olaparib) and IMFINZI ® (durvalumab) at the 2019 American Society of Clinical Oncology (ASCO) Annual...

AstraZeneca Teams Up With PGA Golf Champion Jason Day To Raise Awareness About The Importance Of Biomarker Testing In Lung Cancer

AstraZeneca Teams Up With PGA Golf Champion Jason Day To Raise Awareness About The Importance Of Biomarker Testing In Lung Cancer

AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can...

Change Makers Across The Oncology Community Recognized At 2019 Cancer Community (C2) Awards

Change Makers Across The Oncology Community Recognized At 2019 Cancer Community (C2) Awards

The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards.

Selumetinib Granted US Breakthrough Therapy Designation In Neurofibromatosis Type 1

Selumetinib Granted US Breakthrough Therapy Designation In Neurofibromatosis Type 1

AstraZeneca and Merck & Co., Inc.

Dow Ends Up on 'Constructive' Trade Talks; S&P 500 Logs Best Quarter Since 2009

Dow Ends Up on 'Constructive' Trade Talks; S&P 500 Logs Best Quarter Since 2009

Stocks closes up Friday after U.S. Treasury Secretary Steven Mnuchin says trade talks he held with China were 'constructive.'

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years.

US Futures Gain in Best Quarter Since 2009 as Mnuchin Touts China Trade Progress

US Futures Gain in Best Quarter Since 2009 as Mnuchin Touts China Trade Progress

Global stocks traded higher Friday, lifting U.S. equity markets towards their best opening quarter gain in a decade, as investors crept back into risk markets amid progress in U.S.-China trade talks, modestly higher fixed income yields and the opening trade of the biggest IPO since 2014.

Lyft, Wells Fargo CEO and 'Constructive' Trade Talks - 5 Things You Must Know

Lyft, Wells Fargo CEO and 'Constructive' Trade Talks - 5 Things You Must Know

Stock futures rise after Treasury Secretary Steven Mnuchin says trade talks between the U.S. and China have been 'constructive'; Lyft's IPO is priced at $72 a share, valuing the ride-hailing company at more than $24 billion; Tim Sloan steps down as CEO of Well Fargo.

First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes

First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo (15.

AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019

AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019

Data evaluating the cardiovascular (CV) effects of FARXIGA ® (dapagliflozin) , including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the...

US FDA Approves Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment

US FDA Approves Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin and metformin HCl extended-release) expanding use in patients with type 2 diabetes (T2D)...

BRILINTA's Phase III THEMIS Trial Met Primary Endpoint In Patients With Established Coronary Artery Disease And Type-2 Diabetes

BRILINTA's Phase III THEMIS Trial Met Primary Endpoint In Patients With Established Coronary Artery Disease And Type-2 Diabetes

The Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA ® (ticagrelor) tablets, taken in conjunction with aspirin, showed a statistically-significant reduction in major adverse cardiovascular events (MACE, a composite of...

Hot Cancer Detection Stock Still Has Room to Run

Hot Cancer Detection Stock Still Has Room to Run

Guardant's liquid biopsy lets oncologists see all of the genomic information of a patient's tumor with a simple blood test. The alternative is a tissue biopsy which can be expensive and risky.

Wall Street Futures Tumble After Weakest December Retail Sales in a Decade

Wall Street Futures Tumble After Weakest December Retail Sales in a Decade

U.S. equity futures turned sharply red Thursday after data showed the weakest reading for December retail sales in nine years, erasing earlier gains linked to progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity.

Tanabe Research Labs Announce FDA Acceptance Of Its IND Application For TR1801-ADC (MT-8633), An ADC Targeting CMet Positive Solid Tumors

Tanabe Research Labs Announce FDA Acceptance Of Its IND Application For TR1801-ADC (MT-8633), An ADC Targeting CMet Positive Solid Tumors

SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?

Wall Street Extends Gains on China Trade Talk Optimism; Dollar Hits 2-Month High

Wall Street Extends Gains on China Trade Talk Optimism; Dollar Hits 2-Month High

Wall Street futures extended gains Thursday with investors using signals of moderate progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity to boost the broadest measure of U.S. stocks to a 10% gain for the year.

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.

The New Small Biotechs Heating Up the Medical Cannabis Space

The New Small Biotechs Heating Up the Medical Cannabis Space

These companies are working to plant their flag in a new landscape.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

TheStreet Quant Rating: B (Buy)